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Abstract 
BACKGROUND: Triple negative breast cancer (TNBC) is a breast cancer sub-type that lacks ER, PR and HER-2 
expression. This type tends to be more aggressive than other types of breast cancer, with poor prognosis, distant 
metastases, higher recurrence rate, and lower overall survival. The TNBC is resistant to hormonal therapy, but 
generally very susceptible to chemotherapy. Expression of CD8+ and Foxp3+ were parts of the TIL, which often 
found in TNBC as an immune response to tumour antigens following antigens presenting cell (APC) stimulation.  
AIM: This study was conducted to find out whether the expression of CD8+, Foxp3+ and CD8+/Foxp3+ ratio was 
associated with the stage of TNBC. 
METHODS: This cross-sectional study was conducted from January 2014 until December 2016 at Sanglah 
Hospital with 46 research subjects. Two paraffin blocks were prepared for each sample to examine the CD8+ 
expression and Foxp3+ expression. Data were analysed using the Chi-Square test or Fisher's Exact tests as an 
alternative for bivariate analysis and logistic regression for multivariate analysis. 
RESULTS: On bivariate analysis, we found a low of CD8+ expression in advanced stage (p < 0.001 with OR 3.5; 
CI 1.611-7.727). Expression Foxp3+ in advanced stage (p = 0.482; OR 0.8; CI 0.497-1.374), while the ratio of 
CD8+/Foxp3+ (p = 0.213; OR 2.2; CI 0.650-7.132). On multivariate analysis, a low of CD8+ expression (adjusted 
OR 16.5; CI 3.735-7.370; p < 0.001) was obtained. 
CONCLUSION: Low expression of CD8+ was associated with the advanced stage of TNBC. The risk of becoming 
an advanced stage in TNBC patients with low CD8+ expression was 16.5 times higher than those with high of 
CD8+ expression. High expression of Foxp3+ was not associated with an advanced stage of TNBC. The low 
CD8+/Foxp3+ ratio was not associated with the advanced stage of TNBC. 
 
 
 
Introduction 
 
Triple-negative breast cancer (TNBC) is one 
of the subtypes of breast cancer that has a poor 
prognosis for free survival disease and shorter 
survival overall. The highest prevalence is in African-
American women. Until now, there is no specific 
targeting therapy for TNBC. Significant overlap found 
in BRCA 1 associated breast cancer with TNBC 
phenotype [1].
 
TNBC is aggressive and has higher mortality 
due to metastases and has a high character of cell 
proliferation, poor cell differentiation, and in many 
cases, mutations in the TP53 tumour suppressor 
gene. TNBC often occurs at a younger age (< 40 
years) [2]. TNBC recurrence increases in the first 
three years after diagnosis and decreases after eight 
years [3], and the mortality rate will increase within 5 
years after diagnosed [4].
 
The poor prognosis of TNBC is related to 
tumour grading, lymph node status, tumour size and 
management [1].
 
TNBC sufferers also tend to have 
lower life expectancies but have a better 
chemotherapy response [5].
 
The potential mechanism that causes higher 
lymphocyte infiltration in TNBC because TNBC is a 
subtype of breast cancer that is immunogenic 
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because of genetic instability and increased mutation 
and expressing certain proteins [6]. An increase in 
tumour infiltrating lymphocytes (TIL) in TNBC is 
associated with increased disease-free and overall 
survival and complete pathologic response (pCR) on 
neoadjuvant therapy [6], [7].
 
High pathological complete response (pCR) 
values after neoadjuvant chemotherapy have been 
reported in patients with high levels of expression of 
TIL components such as CD3+, CD4+ and CD3+, 
CD8+, and Forkhead box protein 3 (Foxp3+). High 
pCR values in TNBC were also reported with a high 
CD8+/Foxp3+ (CFR) ratio [8].
 
Tumour infiltration by CD8+ can control 
tumour growth with cytotoxic effects on tumour cells. 
CD8+ expression is associated with a better prognosis 
if found in large quantities. Almost 20% of TNBC 
expresses strong TIL and if the amount of TIL is more 
in the tumour stroma is associated with a higher 
likelihood of healing in the early stages of TNBC. This 
presents that high CD8+ is associated with the early 
stages of TNBC sufferers [9].
 
There is a strong relationship between 
Foxp3+ with the development and progression of 
cancer. Some research evidence shows Foxp3+ 
effectively protects tumours from our body's immune 
response. Foxp3+ in tumours, ascites and peripheral 
blood of cancer patients was stated to be associated 
with a poor prognosis.
10
 This presented that high 
Foxp3+ was associated with advanced stages of 
TNBC sufferers. The high ratio of CD8+/Foxp3+ T 
cells can predict that the clinical outcome is better in 
TNBC patients [11]. This can illustrate that the high 
ratio of CD8+/Foxp3+ T cells is associated with early 
stages in TNBC patients. 
Many studies linking CD8+, Foxp3+ 
expression and CD8+/Foxp3+ ratio with complete 
pathological responses (pCR) to neoadjuvant therapy 
on TNBC patients made us want to know how the 
relationship of CD8+, Foxp3+, and CD8+/Foxp3+ 
expression to TNBC patients at Sanglah General 
Hospital Denpasar. 
 
 
Methods 
 
We conducted a cross-sectional study of 46 
samples of TNBC patients (fulfilling inclusion and 
exclusion criteria) recorded from January 2014 to 
December 2016 at Sanglah General Hospital. 
Furthermore, the data is taken from the medical 
record to find out the age and clinical stage of TNBC 
sufferers as well as from the Anatomical Pathology 
report obtained from all TNBC patients who 
underwent a diagnostic procedure with biopsy or 
surgery. All operating specimens are then processed 
in paraffin blocks. The subsequent examination was 
performed by immunohistochemistry to determine 
CD8+ and Foxp3+ expressions. 
The collected data were analysed using the 
Chi-Square test or Fisher's Exact test as an 
alternative for bivariate analysis and logistic 
regression for multivariate analysis. 
 
 
Results 
 
Characteristics of the 46 research subjects 
that we obtained can be seen in Table 1. The data on 
the subject of this study showed an age range 
between 31-75 years, with an average age of 47.6 
years. The age grouping in this study was the early 
age group (< 40 years) and the advanced age group 
(> 40 years). From the table, it can be seen that the 
early age group is 13 (28.3%), and the elderly group is 
33 (71.7%). Grading in this study was high grading 
groups as much as 28 (60.9%), low grading groups as 
many as 14 (30.4%) and unknown groups grading as 
many as 4 (8.7%). The clinical stage, which is the 
dependent variable in this study, is divided into 2, 
namely the advanced stage group (stage III and IV) 
and the early stage group (stage I and II). From the 
table, it was found that the advanced stage group was 
26 (56.5%), and the early stage group was 20 
(43.5%). For the low CD8+ expression group, there 
were 25 (54.3%), and the number of high CD8+ 
expressions was 21 (45.7%). 
Whereas for the high Foxp3+ expression 
group, 32 (69.6%) and low Foxp3+ expressions were 
14 (30.4%). The low CFR group (CD8+/Foxp3+) ratio 
was 39 (84.8%) while the high CFR group was 7 
(15.2%). Based on the results of the bivariate analysis 
(Table 2), the low CD8+ expression group found at an 
advanced stage was 84.0% while in the high CD8+ 
expression group at an advanced stage as much as 
23.8%. Based on statistical tests using the Chi-Square 
test showed that the relationship was significant (p < 
0.001) with a 95% confidence interval of 1.611-7.727. 
Table 1: An Overview of the characteristic of the research 
subjects 
Variable n = 46 
Age (year), average ± SD 47.6 ± 11.5 
≤ 40 years 13 (28.3) 
> 40 years 33 (71.7) 
Grading  
High 28 (60.9) 
Low 14 (30.4) 
Unknown 4 (8.7) 
Stage  
Advanced (III-IV) 26 (56.5) 
Early (I-II) 20 (43.5) 
CD8+  
Low 25 (54.3) 
High 21 (45.7) 
Foxp3+  
High 32 (69.6) 
Low 14 (30.4) 
CFR (Rasio CD8+/Foxp3+)  
Low 39 (84.8) 
High 7 (15.2) 
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The high Foxp3+ expression group was found 
at an advanced stage of 53.1% and 64.3% in the 
Foxp3+ low expression group. Based on statistical 
tests using the Fisher Exact test, the relationship was 
not significant (p = 0.482) with a 95% confidence 
interval of 0.497-1.374. 
Table 2: Bivariate analysis of CD8+, Foxp3+, and CFR 
expressions (CD8+/Foxp3+ ratio) with clinical stage 
Variable Clinical Stage OR 95% P Value 
Advanced Early 
CD8+ 
Low 
High 
Foxp3+ 
High 
Low 
CFR 
Low 
High 
 
21 (84.0) 
5 (23.8) 
 
17 (53.1) 
9 (64.3) 
 
24 (61.5) 
2 (28.6) 
 
4 (16.0) 
16 (76.2) 
 
15 (46.9) 
5 (35.7) 
 
14 (38.5) 
5 (71.4) 
 
3.5 
 
 
0.8 
 
 
2.2 
 
1.611-7.727 
 
 
0.497-1.374 
 
 
0.650-7.132 
 
< 0.001
a
 
 
 
0.482
b
 
 
 
0.213
b
 
a
Uji Chi-Square; 
b
Uji Fisher’s Exact. 
 
In the low CFR expression group at an 
advanced stage as much as 61.5% while in the high 
CFR expression group as much as 28.6%. But based 
on statistical tests using the Fisher Exact test, the 
relationship was not significant (p = 0.213) with a 95% 
confidence interval of 0.650-7.132. 
Based on the bivariate analysis, it is 
necessary to continue the multivariate analysis to 
assess the pure effect of each variable. The variables 
included in the multivariate test are age variables and 
CD8+ expressions. Grading variables are not included 
because the data is missing so that it does not 
represent in its entirety (Table 3). Based on the table, 
there is a pure relationship between low CD8+ 
expression and advanced stage in TNBC patients with 
adjusted OR 16.5 after calculating age variables. 
Table 3: Multivariable Analysis of CD8+ Interaction with 
Clinical Stages after controlling the age 
Variable Adjusted OR 95% CI p-value 
Low CD8+  
Age 
16.5 
0.9 
3.735 – 7.370 
0.182 – 4.753 
< 0.001 
0.930 
 
 
 
Discussion 
 
The TNBC breast cancer subtype compared 
to other breast cancer subtypes is associated with 
younger age (< 40 years) when diagnosed [2], [12], 
[13]. The earlier the age of cancer patients the greater 
the influence of internal factors on the occurrence of 
malignancy compared to external factors, especially 
there is a delay in diagnosis and has been found in an 
advanced stage, the prognosis is getting worse.
14
 In 
this study, the whole study subjects with TNBC were 
found to be older (> 40 years), namely 71.7% 
compared to young age (28.3%). Besides that, there 
were more advanced groups from the early stage 
group (56.5% vs 43.5%). This may be due to the 
delay of the patient in examining the health service 
centre. 
In breast cancer, grading is a prognostic 
factor where high grading has more aggressive 
behaviour and poor prognosis; the recurrence rates 
are four times more than low grading [4]. The poor 
prognosis of TNBC is related to tumour grading, 
lymph node status, size tumour, and management [1]. 
In this study, grading was included as a confounding 
variable. The above is by this study where high 
grading was 60.9%; low grading was 30.4% while 
unknown grading was 8.7%. 
From the characteristics of the research 
subjects above, the stadium obtained more groups 
than the early group stadiums. This means that TIL, in 
this case, is CD8+ with a lower expression more than 
high CD8+ expression. This is consistent with the 
results of a study that cites CD8+ low (54.3%) more 
than high CD8+ expression (45.7%). Meanwhile, for 
Foxp3+, according to the characteristics of the subject 
of this study, Foxp3+ groups (69.6%) were higher than 
Foxp3+ low expressions (30.4%). Likewise, from the 
CFR group (CD8+/Foxp3+ ratio), there was a lower 
CFR group (84.8%) more than the high CFR group 
(15.2%). 
In the advanced stage, it was found that the 
low CD8+ expression group was 84.0% while the high 
CD8+ expression group was 23.8%. This shows that 
low CD8+ expression at an advanced stage is not 
capable of carrying out its function as surveillance by 
recognising and killing malignant cells that express 
peptides produced by mutant cell proteins or 
oncogenic viral proteins presented through MHC class 
I [15].
 
There is a pure relationship between low 
CD8+ expression and advanced stage (p < 0.001) in 
TNBC patients with adjusted OR 16.5 which means 
that the risk of TNBC patients with low CD8+ 
expression is 16.5 times higher than TNBC patients 
with high CD8+ expression. This is consistent with 
research that says that nearly 20% of TNBC 
expresses strong TIL and if the amount of TIL is more 
in the tumour stroma is associated with a higher 
likelihood of healing in the early stages of TNBC [9]. 
The distribution of Foxp3+ expression at an 
advanced stage showed that the high Foxp3+ 
expression (53.1%) was lower than Foxp3+ low 
expression (64.3%) and statistical analysis of Foxp3+ 
high expression with an advanced stage was not 
proven to have a significant relationship (p = 0.482). 
This is different from previous studies which stated 
that there was an increase in the appearance of 
CD4+, CD25+, Foxp3+ T Cell in malignancies such as 
the lungs, head and neck, ovary, gastrointestinal, and 
skin [10]. This shows that at an advanced stage, 
Foxp3 + expressions should be higher than low 
Foxp3+ expressions. 
The causes of the absence of such 
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relationships include two hypotheses. First, as it is 
known that tumour progression is not only influenced 
by Foxp3 +, but there are also other influential factors 
such as CTLA4 and PD-1. T cell activity requires 
antigen recognition by TCR and the introduction of 
costimulatory, mainly B7 by CD8+. CTLA-4 resembles 
CD8+ receptor activity, is bound to B7 molecules. 
CTLA-4 has a greater affinity ability than CD8+ to B7 
family receptors thus preventing B7 costimulatory in 
APC from CD8+ bond, then produces a signal that 
inhibits T cells which cause the non-working 
interaction of APC-complex T cells. CTLA-4 will cause 
no T cell sensitisation, T cells become anergic, and 
even T cell apoptosis can occur. Ultimately energy 
from T cells will correlate to the degree of 
differentiation and progression of cancer cells [15]. 
Other receptor blockers on CD8+ family are PD-1 
(Programmed Cell Death 1). The use of PD-1 by other 
ligands leads to T cell inactivity. It is said that CTLA-4 
main function is to control initial T cells that are active 
in lymphoid organs while PD-1 plays an important role 
in limiting the response to effector cell differentiation in 
peripheral tissues [15].
 
Second, in the early stages, 
higher Foxp3+ expressions were more found than 
Foxp3+ low expressions. This is probably because 
Foxp3+ circulates a lot in the peripheral circulation but 
is mostly in FoxP3+ naive T cell conditions, so it has 
not carried out its activities to inhibit CD8. This is by 
the results of the study that in the circulation of the 
Treg cell periphery, it is 5-10% naive CD4+ T cell [16]. 
In the advanced stage, the CFR group was 
low (61.5%) while in the CFR group it was high 
(28.6%), but the statistical test showed that the 
relationship was not significant (p = 0.213). This is 
because in the calculation of the CFR there are 2 
independent variables, namely CD8+ and Foxp3+. 
The Foxp3 variable statistically did not show a 
significant relationship causing the results of the CFR 
to be meaningless. 
In conclusion, low CD8+ expression is 
associated with advanced stages of TNBC sufferers. 
High Foxp3+ expression is not associated with 
advanced stages of TNBC sufferers. Low 
CD8+/Foxp3+ ratio is not associated with advanced 
stages of TNBC sufferers. 
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